¡Desconecta con la aplicación Player FM !
Innovations in glaucoma care: Targeting pathophysiology to expand treatment options
Manage episode 443978272 series 3389426
touchEXPERT OPINIONS for touchOPHTHALMOLOGY
Listen to leading experts describe the pathophysiology of open-angle glaucoma and discuss how it is targeted by current and emerging treatment options, while providing insights on how different agents and combinations are used in practice.
The experts
- Angelo P Tanna, MD - Northwestern University Feinberg School of Medicine, Chicago, IL, USA
- Courtney E Bovee, MD - Bovee Eye, Tampa Bay, FL, USA
- Joseph F Panarelli, MD - NYU Langone Eye Center, New York, NY, USA
This touchPODCAST is for HCPs only.
This activity is funded by an independent medical education grant from Alcon Vision, LLC and is jointly provided by USF Health and touchIME.
For further information visit our website: https://touchOPHTHALMOLOGY.com/
102 episodios
Manage episode 443978272 series 3389426
touchEXPERT OPINIONS for touchOPHTHALMOLOGY
Listen to leading experts describe the pathophysiology of open-angle glaucoma and discuss how it is targeted by current and emerging treatment options, while providing insights on how different agents and combinations are used in practice.
The experts
- Angelo P Tanna, MD - Northwestern University Feinberg School of Medicine, Chicago, IL, USA
- Courtney E Bovee, MD - Bovee Eye, Tampa Bay, FL, USA
- Joseph F Panarelli, MD - NYU Langone Eye Center, New York, NY, USA
This touchPODCAST is for HCPs only.
This activity is funded by an independent medical education grant from Alcon Vision, LLC and is jointly provided by USF Health and touchIME.
For further information visit our website: https://touchOPHTHALMOLOGY.com/
102 episodios
Усі епізоди
×Bienvenido a Player FM!
Player FM está escaneando la web en busca de podcasts de alta calidad para que los disfrutes en este momento. Es la mejor aplicación de podcast y funciona en Android, iPhone y la web. Regístrate para sincronizar suscripciones a través de dispositivos.